Loading…
Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest
While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is m...
Saved in:
Published in: | mAbs 2014-05, Vol.6 (3), p.679-688 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3 |
container_end_page | 688 |
container_issue | 3 |
container_start_page | 679 |
container_title | mAbs |
container_volume | 6 |
creator | Derfus, Gayle E Dizon-Maspat, Jemelle Broddrick, Jared T Velayo, Arleene C Toschi, Josh D Santuray, Rodell T Hsu, Stephen K Winter, Charles M Krishnan, Rajesh Amanullah, Ashraf |
description | While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to the higher molecular density across a given path-length. Color is therefore a product quality attribute that must be well-understood and controlled, to demonstrate process consistency and enable clinical trial blinding. Upon concentration of an IgG4 product at the 2000 L manufacturing scale, variability in product color, ranging from yellow to red, was observed. A small-scale experimental model was developed to assess the effect of processing conditions (medium composition and harvest conditions) on final bulk drug substance (BDS) color. The model was used to demonstrate that, for two distinct IgG4 products, red coloration occurred only in the presence of disulfide reduction-mediated antibody dissociation. The red color-causing component was identified as vitamin B
12
, in the hydroxocobalamin form, and the extent of red color was correlated with the cobalt (vitamin B
12
) concentration in the final pools. The intensity of redness in the final BDS was modulated by changing the concentration of vitamin B
12
in the cell culture media. |
doi_str_mv | 10.4161/mabs.28257 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4011912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1516722484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3</originalsourceid><addsrcrecordid>eNptkVtLJDEQhcOyyyrqy_6AJY-yMJrKJJ3uF0HFGwjCsvscKpd2ot0dN-kemX9vxtFhBeulCvLVySkOIT-AHQmo4LhHk494zaX6QnahEXzGasW-bueK75CDnB_YuhQDxb6THS6k5FXDdsnjb--ojV1Mpd_cXwlqccplNiu6DCP2YaBnwGmbYk-t7zpqp26ckqe9dwHLam_CUPjnMC6oC3nq2uA8LXKTHUMcKI50gWnp87hPvrXYZX_w1vfI38uLP-fXs9u7q5vz09uZLZ7UTMqmNhVw14A1aEUDsjZQcyVQWpzDXFXKWm9Y7YRTQgiA2ppynGeuqYSf75GTje7TZIpL64cxYaefUugxrXTEoD--DGGh7-NSCwbQAC8Ch28CKf6binPdh7w-Hgcfp6xBQqU4F7Uo6K8NalPMOfl2-w0wvQ5IrwPSrwEV-Of_xrboexwFkBsgDG1MPT7H1Dk94qrk0yYcbMh6_onwC-Wgnrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1516722484</pqid></control><display><type>article</type><title>Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest</title><source>PubMed Central</source><creator>Derfus, Gayle E ; Dizon-Maspat, Jemelle ; Broddrick, Jared T ; Velayo, Arleene C ; Toschi, Josh D ; Santuray, Rodell T ; Hsu, Stephen K ; Winter, Charles M ; Krishnan, Rajesh ; Amanullah, Ashraf</creator><creatorcontrib>Derfus, Gayle E ; Dizon-Maspat, Jemelle ; Broddrick, Jared T ; Velayo, Arleene C ; Toschi, Josh D ; Santuray, Rodell T ; Hsu, Stephen K ; Winter, Charles M ; Krishnan, Rajesh ; Amanullah, Ashraf</creatorcontrib><description>While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to the higher molecular density across a given path-length. Color is therefore a product quality attribute that must be well-understood and controlled, to demonstrate process consistency and enable clinical trial blinding. Upon concentration of an IgG4 product at the 2000 L manufacturing scale, variability in product color, ranging from yellow to red, was observed. A small-scale experimental model was developed to assess the effect of processing conditions (medium composition and harvest conditions) on final bulk drug substance (BDS) color. The model was used to demonstrate that, for two distinct IgG4 products, red coloration occurred only in the presence of disulfide reduction-mediated antibody dissociation. The red color-causing component was identified as vitamin B
12
, in the hydroxocobalamin form, and the extent of red color was correlated with the cobalt (vitamin B
12
) concentration in the final pools. The intensity of redness in the final BDS was modulated by changing the concentration of vitamin B
12
in the cell culture media.</description><identifier>ISSN: 1942-0862</identifier><identifier>ISSN: 1942-0870</identifier><identifier>EISSN: 1942-0870</identifier><identifier>EISSN: 1942-0862</identifier><identifier>DOI: 10.4161/mabs.28257</identifier><identifier>PMID: 24552690</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Animals ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - isolation & purification ; bioprocess ; Chemistry, Pharmaceutical ; Chinese hamster ovary ; CHO Cells ; Cobalt - chemistry ; Color ; Colorimetry ; Cricetulus ; Culture Media - chemistry ; Disulfides - chemistry ; high concentration ; Humans ; Immunoglobulin G - administration & dosage ; Immunoglobulin G - chemistry ; Immunoglobulin G - isolation & purification ; Light ; monoclonal antibody ; Oxidation-Reduction ; Vitamin B 12 - chemistry</subject><ispartof>mAbs, 2014-05, Vol.6 (3), p.679-688</ispartof><rights>Copyright © 2014 Landes Bioscience 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3</citedby><cites>FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011912/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011912/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24552690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Derfus, Gayle E</creatorcontrib><creatorcontrib>Dizon-Maspat, Jemelle</creatorcontrib><creatorcontrib>Broddrick, Jared T</creatorcontrib><creatorcontrib>Velayo, Arleene C</creatorcontrib><creatorcontrib>Toschi, Josh D</creatorcontrib><creatorcontrib>Santuray, Rodell T</creatorcontrib><creatorcontrib>Hsu, Stephen K</creatorcontrib><creatorcontrib>Winter, Charles M</creatorcontrib><creatorcontrib>Krishnan, Rajesh</creatorcontrib><creatorcontrib>Amanullah, Ashraf</creatorcontrib><title>Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest</title><title>mAbs</title><addtitle>MAbs</addtitle><description>While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to the higher molecular density across a given path-length. Color is therefore a product quality attribute that must be well-understood and controlled, to demonstrate process consistency and enable clinical trial blinding. Upon concentration of an IgG4 product at the 2000 L manufacturing scale, variability in product color, ranging from yellow to red, was observed. A small-scale experimental model was developed to assess the effect of processing conditions (medium composition and harvest conditions) on final bulk drug substance (BDS) color. The model was used to demonstrate that, for two distinct IgG4 products, red coloration occurred only in the presence of disulfide reduction-mediated antibody dissociation. The red color-causing component was identified as vitamin B
12
, in the hydroxocobalamin form, and the extent of red color was correlated with the cobalt (vitamin B
12
) concentration in the final pools. The intensity of redness in the final BDS was modulated by changing the concentration of vitamin B
12
in the cell culture media.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - isolation & purification</subject><subject>bioprocess</subject><subject>Chemistry, Pharmaceutical</subject><subject>Chinese hamster ovary</subject><subject>CHO Cells</subject><subject>Cobalt - chemistry</subject><subject>Color</subject><subject>Colorimetry</subject><subject>Cricetulus</subject><subject>Culture Media - chemistry</subject><subject>Disulfides - chemistry</subject><subject>high concentration</subject><subject>Humans</subject><subject>Immunoglobulin G - administration & dosage</subject><subject>Immunoglobulin G - chemistry</subject><subject>Immunoglobulin G - isolation & purification</subject><subject>Light</subject><subject>monoclonal antibody</subject><subject>Oxidation-Reduction</subject><subject>Vitamin B 12 - chemistry</subject><issn>1942-0862</issn><issn>1942-0870</issn><issn>1942-0870</issn><issn>1942-0862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNptkVtLJDEQhcOyyyrqy_6AJY-yMJrKJJ3uF0HFGwjCsvscKpd2ot0dN-kemX9vxtFhBeulCvLVySkOIT-AHQmo4LhHk494zaX6QnahEXzGasW-bueK75CDnB_YuhQDxb6THS6k5FXDdsnjb--ojV1Mpd_cXwlqccplNiu6DCP2YaBnwGmbYk-t7zpqp26ckqe9dwHLam_CUPjnMC6oC3nq2uA8LXKTHUMcKI50gWnp87hPvrXYZX_w1vfI38uLP-fXs9u7q5vz09uZLZ7UTMqmNhVw14A1aEUDsjZQcyVQWpzDXFXKWm9Y7YRTQgiA2ppynGeuqYSf75GTje7TZIpL64cxYaefUugxrXTEoD--DGGh7-NSCwbQAC8Ch28CKf6binPdh7w-Hgcfp6xBQqU4F7Uo6K8NalPMOfl2-w0wvQ5IrwPSrwEV-Of_xrboexwFkBsgDG1MPT7H1Dk94qrk0yYcbMh6_onwC-Wgnrw</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Derfus, Gayle E</creator><creator>Dizon-Maspat, Jemelle</creator><creator>Broddrick, Jared T</creator><creator>Velayo, Arleene C</creator><creator>Toschi, Josh D</creator><creator>Santuray, Rodell T</creator><creator>Hsu, Stephen K</creator><creator>Winter, Charles M</creator><creator>Krishnan, Rajesh</creator><creator>Amanullah, Ashraf</creator><general>Taylor & Francis</general><general>Landes Bioscience</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201405</creationdate><title>Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest</title><author>Derfus, Gayle E ; Dizon-Maspat, Jemelle ; Broddrick, Jared T ; Velayo, Arleene C ; Toschi, Josh D ; Santuray, Rodell T ; Hsu, Stephen K ; Winter, Charles M ; Krishnan, Rajesh ; Amanullah, Ashraf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - isolation & purification</topic><topic>bioprocess</topic><topic>Chemistry, Pharmaceutical</topic><topic>Chinese hamster ovary</topic><topic>CHO Cells</topic><topic>Cobalt - chemistry</topic><topic>Color</topic><topic>Colorimetry</topic><topic>Cricetulus</topic><topic>Culture Media - chemistry</topic><topic>Disulfides - chemistry</topic><topic>high concentration</topic><topic>Humans</topic><topic>Immunoglobulin G - administration & dosage</topic><topic>Immunoglobulin G - chemistry</topic><topic>Immunoglobulin G - isolation & purification</topic><topic>Light</topic><topic>monoclonal antibody</topic><topic>Oxidation-Reduction</topic><topic>Vitamin B 12 - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Derfus, Gayle E</creatorcontrib><creatorcontrib>Dizon-Maspat, Jemelle</creatorcontrib><creatorcontrib>Broddrick, Jared T</creatorcontrib><creatorcontrib>Velayo, Arleene C</creatorcontrib><creatorcontrib>Toschi, Josh D</creatorcontrib><creatorcontrib>Santuray, Rodell T</creatorcontrib><creatorcontrib>Hsu, Stephen K</creatorcontrib><creatorcontrib>Winter, Charles M</creatorcontrib><creatorcontrib>Krishnan, Rajesh</creatorcontrib><creatorcontrib>Amanullah, Ashraf</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>mAbs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Derfus, Gayle E</au><au>Dizon-Maspat, Jemelle</au><au>Broddrick, Jared T</au><au>Velayo, Arleene C</au><au>Toschi, Josh D</au><au>Santuray, Rodell T</au><au>Hsu, Stephen K</au><au>Winter, Charles M</au><au>Krishnan, Rajesh</au><au>Amanullah, Ashraf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest</atitle><jtitle>mAbs</jtitle><addtitle>MAbs</addtitle><date>2014-05</date><risdate>2014</risdate><volume>6</volume><issue>3</issue><spage>679</spage><epage>688</epage><pages>679-688</pages><issn>1942-0862</issn><issn>1942-0870</issn><eissn>1942-0870</eissn><eissn>1942-0862</eissn><abstract>While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to the higher molecular density across a given path-length. Color is therefore a product quality attribute that must be well-understood and controlled, to demonstrate process consistency and enable clinical trial blinding. Upon concentration of an IgG4 product at the 2000 L manufacturing scale, variability in product color, ranging from yellow to red, was observed. A small-scale experimental model was developed to assess the effect of processing conditions (medium composition and harvest conditions) on final bulk drug substance (BDS) color. The model was used to demonstrate that, for two distinct IgG4 products, red coloration occurred only in the presence of disulfide reduction-mediated antibody dissociation. The red color-causing component was identified as vitamin B
12
, in the hydroxocobalamin form, and the extent of red color was correlated with the cobalt (vitamin B
12
) concentration in the final pools. The intensity of redness in the final BDS was modulated by changing the concentration of vitamin B
12
in the cell culture media.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>24552690</pmid><doi>10.4161/mabs.28257</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1942-0862 |
ispartof | mAbs, 2014-05, Vol.6 (3), p.679-688 |
issn | 1942-0862 1942-0870 1942-0870 1942-0862 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4011912 |
source | PubMed Central |
subjects | Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - isolation & purification bioprocess Chemistry, Pharmaceutical Chinese hamster ovary CHO Cells Cobalt - chemistry Color Colorimetry Cricetulus Culture Media - chemistry Disulfides - chemistry high concentration Humans Immunoglobulin G - administration & dosage Immunoglobulin G - chemistry Immunoglobulin G - isolation & purification Light monoclonal antibody Oxidation-Reduction Vitamin B 12 - chemistry |
title | Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Red%20colored%20IgG4%20caused%20by%20vitamin%20B12%20from%20cell%20culture%20media%20combined%20with%20disulfide%20reduction%20at%20harvest&rft.jtitle=mAbs&rft.au=Derfus,%20Gayle%20E&rft.date=2014-05&rft.volume=6&rft.issue=3&rft.spage=679&rft.epage=688&rft.pages=679-688&rft.issn=1942-0862&rft.eissn=1942-0870&rft_id=info:doi/10.4161/mabs.28257&rft_dat=%3Cproquest_pubme%3E1516722484%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2697-5598b612d91cbac49158b18274a5ca313767cceb08d4d7444118cb007e0d964e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1516722484&rft_id=info:pmid/24552690&rfr_iscdi=true |